Pre-order Enquiry
Request Free Sample
Global Factor IX Deficiency Treatment Market Size, Status and Forecast 2019-2025
SKU ID : QYR-14194464 | Publishing Date : 09-May-2019 | No. of pages : 90
Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.
In this market study, analysts have estimated the prophylaxis segment to dominate the factor IX deficiency treatment market during the forecast period. Factors such a low cost and high efficiency are the key contributors to the dominance of this segment in the global market.
The global hemophilia B drugs market is expected to grow at a moderate pace during the forecast period. The growing incidence of hemophilia B is expected to drive the market growth. Also, the increasing demand for novel recombinant extended half-life products coupled with the emergence of monoclonal antibodies and gene therapy products will propel the growth of this segment in the next few years.
In 2018, the global Factor IX Deficiency Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Factor IX Deficiency Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Factor IX Deficiency Treatment development in United States, Europe and China.
The key players covered in this study
Pfizer
Shire
Novo Nordisk
Biogen
CSL Behring
...
Market segment by Type, the product can be split into
Hemophilia B
Hemophilia B Inhibitors
Market segment by Application, split into
Hospitals
Clinics
Other
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Factor IX Deficiency Treatment status, future forecast, growth opportunity, key market and key players.
To present the Factor IX Deficiency Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Factor IX Deficiency Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
In this market study, analysts have estimated the prophylaxis segment to dominate the factor IX deficiency treatment market during the forecast period. Factors such a low cost and high efficiency are the key contributors to the dominance of this segment in the global market.
The global hemophilia B drugs market is expected to grow at a moderate pace during the forecast period. The growing incidence of hemophilia B is expected to drive the market growth. Also, the increasing demand for novel recombinant extended half-life products coupled with the emergence of monoclonal antibodies and gene therapy products will propel the growth of this segment in the next few years.
In 2018, the global Factor IX Deficiency Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Factor IX Deficiency Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Factor IX Deficiency Treatment development in United States, Europe and China.
The key players covered in this study
Pfizer
Shire
Novo Nordisk
Biogen
CSL Behring
...
Market segment by Type, the product can be split into
Hemophilia B
Hemophilia B Inhibitors
Market segment by Application, split into
Hospitals
Clinics
Other
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Factor IX Deficiency Treatment status, future forecast, growth opportunity, key market and key players.
To present the Factor IX Deficiency Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Factor IX Deficiency Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
